gefurulimab   Click here for help

GtoPdb Ligand ID: 14698

Synonyms: ALXN-1720 | ALXN1720 | CON-9978 | Klygefa® | TPP-2511
Immunopharmacology Ligand
Compound class: Antibody
Comment: Gefurulimab (ALXN1720) is a bispecific VHH nanobody that binds complement component C5 (in the terminal complement cascade) and serum albumin [1]. It is designed to block enzymatic cleavage of C5 (into biologically active C5a and C5b fragments), and reduce inflammation. Binding to serum albumin extends the agent's systemic half-life and therapeutic window.
No information available.
Summary of Clinical Use Click here for help
Gefurulimab (ALXN1720) was progressed to clinical evaluations to determine immunomodulatory potential in complement-mediated diseases [2].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05556096 Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis Phase 3 Interventional Alexion Pharmaceuticals, Inc.
NCT06607627 PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis Phase 3 Interventional Alexion Pharmaceuticals, Inc.